Hoxter

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

This research aims to generate real-world evidence about the use of the da Vinci Surgical Systems for gynecological procedures within the German healthcare system. It is a prospective, non-interventional, multi-center, post-market clinical study focused on women with gynecological disorders who are candidates for robotic-assisted surgery. Participants are enrolled consecutively if they are undergoing robotic-assisted surgery with the da Vinci system or if they are eligible for robotic surgery but receive a non-da Vinci surgical procedure. The study collects data on these two groups to compare outcomes related to their surgical treatment choices. During the study, researchers will monitor complications related to surgery up to 30 days and patient-reported outcomes up to 12 months. They will also examine treatment decisions as reported by physicians. Additional measures include assessing the impact of patient characteristics and surgeon experience on outcomes and complications, patient quality of life and function, recurrence rates, and surgical details. Participants will be observed through follow-up visits and data collection lasting up to 12 months after surgery.